The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Sandoz Inc. "Sandoz", in cooperation with the U.S. Consumer Product Safety Commission ("CPSC") is implementing a CPSC-approved corrective action plan concerning two lot numbers of Aprepitant Capsules 125 mg and nine lot numbers of Lidocaine and Prilocaine 2.5%/2.5% Cream. The packaging of these lot numbers is not child-resistant as required by the Poison Prevention Packaging Act, posing a risk of harm if children ingest the drugs or put the cream on their skin. These products are intended for institutional use only and are marked accordingly. However, a relatively small number of units bearing the NDC and lot numbers listed below were distributed by wholesalers into the retail market.

Product Description	**NDC Number**	**Lot Number**	**Expiration Date**
Aprepitant Capsules 125 mg, blister pack of 6 capsules	0781-2323-68 Carton	LK3209 LC6454	04/2024
	0781-2323-06 Blister Pack		12/2023
Lidocaine and Prilocaine 2.5%/2.5% Cream	0168-0357-56 Carton	LA2782 LA2784 LV0667 LX5350	03/2024
	0168-0357-55 Carton	MA1640 MB3205 LA2785 LR9041	03/2024
	0168-0357-05 Tube	MB3209	04/2024
			03/2023
			11/2023
			04/2024
			03/2023
			02/2024